Biotech entity

Collegium Pharmaceutical, Inc.

Company COLL

All 2 tracked stories fall under one category: pharma. Collegium Pharmaceutical, Inc. is most often covered alongside Xtampza ER, which appears in 2 of these 2 stories. That works out to roughly 0.8 stories per week across a 17-day span.

Last mentioned: Mar 15, 2026

Entity pulse

Recent coverage · Collegium Pharmaceutical, Inc.

2 stories
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Collegium Pharmaceutical, Inc.

All 2 tracked stories fall under one category: pharma. Collegium Pharmaceutical, Inc. is most often covered alongside Xtampza ER, which appears in 2 of these 2 stories. That works out to roughly 0.8 stories per week across a 17-day span. Source depth averages 2 original sources per story, versus 3.6 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 6 for that window. Collegium Pharmaceutical, Inc. appears in 2 tracked Biotech stories published from February 27, 2026 through March 15, 2026.

Stories tracked
2
Per week
0.8
Sources per story
2

Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 184 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Collegium Pharmaceutical, Inc.. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning Collegium Pharmaceutical, Inc. 2

Pharma Neutral

Eventide Asset Management LLC Trims Stake in Collegium Pharmaceutical, Inc.

Eventide Asset Management LLC has reduced its position in Collegium Pharmaceutical, Inc. (COLL), though it maintains a significant remaining stake valued at $83.65 million. This institutional shift comes as Collegium continues to integrate recent acquisitions and navigate the complex regulatory landscape of the specialty pain management market.

2 sources

Collegium Pharmaceutical, Inc. is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.